<DOC>
	<DOCNO>NCT00381901</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , trastuzumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . It yet know whether give trastuzumab 6 month effective give trastuzumab 1 year treat patient breast cancer . PURPOSE : This randomized phase III trial study trastuzumab see well work give 6 month compare 12 month treat woman nonmetastatic breast cancer remove surgery .</brief_summary>
	<brief_title>Trastuzumab 6 Months 1 Year Treating Women With Nonmetastatic Breast Cancer That Can Be Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare disease-free survival woman nonmetastatic , resectable breast cancer treat adjuvant trastuzumab ( Herceptin® ) 6 month vs 12 month . Secondary - Compare cardiotoxicity patient receive regimen . - Compare cardiotoxicity disease-free survival patient receive concurrent trastuzumab chemotherapy vs sequential administration . - Correlate HER-2 polymorphism disease-free survival/cardiotoxicity patient . OUTLINE : This randomize , control , multicenter study . Patients stratify accord participate center , modality adjuvant chemotherapy ( concurrent vs sequential ) , adjuvant hormonal therapy ( yes v ) . Patients randomize 1 2 treatment arm . - Arm I ( control arm , 12-month therapy ) : Patients continue receive trastuzumab ( Herceptin® ) IV total 12 month therapy complete absence disease progression unacceptable toxicity . - Arm II ( experimental arm , 6-month therapy ) : Patients continue receive trastuzumab* IV total 6 month therapy complete absence disease progression unacceptable toxicity . NOTE : *Patients already finish 6 month trastuzumab randomization receive trastuzumab . Some patient undergo blood collection HER-2 polymorphism analysis . After completion study therapy , patient follow periodically approximately 5 year . PROJECTED ACCRUAL : A total 7,000 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma breast Nonmetastatic disease Positive negative axillary node Tumor size ≥ 10 mm Resectable disease Must receive ≥ 4 course chemotherapy disease A 12month adjuvant treatment trastuzumab ( Herceptin® ) initiate Informed consent form must sign third sixth month trastuzumab therapy Overexpression HER2 invasive component primary tumor indicate 1 following : 3+ immunohistochemistry ( IHC ) 2+ IHC confirmation fluorescent situ hybridization ( FISH ) chromogenic situ hybridization ( CISH ) Hormone receptor status specify PATIENT CHARACTERISTICS : Female Menopausal status specify LVEF consider favorable continue trastuzumab treatment measure echocardiography MUGA 24 month begin adjuvant trastuzumab No serious cardiac illness medical condition preclude trastuzumab treatment , include follow : History document congestive heart failure Highrisk uncontrolled arrhythmias Angina pectoris require antianginal medication Severe dyspnea rest oxygendependent No known hypersensitivity trastuzumab , murine protein , excipients Not pregnant nursing No social , geographical , psychological condition would preclude study participation PRIOR CONCURRENT THERAPY : See Disease Characteristics Other prior antiHER2 therapy allow No prior trastuzumab initiation trastuzumab adjuvant therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IA breast cancer</keyword>
	<keyword>stage IB breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
</DOC>